Background
Glioma, the most frequently-seen intracranial tumor in the world, is characterized by invasive growth and active angiogenesis [1] . Unfortunately, despite the surgical resection, radiotherapy, and chemotherapy, the median survival time among the glioma population is only 16 to 19 months, while the 2-year survival rate is approximately 25% to 30%, even though excision, radiotherapy, and chemotherapy may be available [2, 3] . Thus, there is an urgently need to further investigate effective diagnosis and treatment methods, considering the poor prognosis of glioma.
As a type of protein antigen, the normal expression of cancertestis antigen (CTA) can only be detected in the reproductive cells of adult testis, but abnormal expression can be detected in a variety of human cancers [4] . PAS domain containing repressor 1 (PASD1), one of the CTAs known as CT63 or CT64 (https://www.ncbi.nlm.nih.gov/gene/139135), has been newly identified as a CTA and has been reported to be abnormally expressed in a variety of malignancies [5] . PASD1, a type of CT-X antigen, has been localized in chromosome Xq28, but it does not belong to the multi-gene family. PASD1 expression in glioma tissues as well as normal adjacent tissues was evaluated in this study to examine its prognostic and clinicopathological value. In addition, the role of PASD1 in the pathogenesis of glioma was also explored, and its effects on the glioma cell line LN229 in vivo was evaluated. Our findings demonstrated that PASD1 might work as a new indicator of the poor prognosis for glioma patients, which might thereby serve as a potential diagnostic and therapeutic marker in glioma.
Material and Methods

Tissue specimens
We collected 155 tissue samples from the First Hospital Affiliated to Zhengzhou University from May 2016 to May 2018 (Table 1) . Meanwhile, normal brain tissue samples were provided from the Department of Histology and Embryology of Zhengzhou University and served as the controls. Tumor staging was assessed according to the 2007 World Health Organization (WHO) classification of nervous system tumors. Inform consent was obtained from patients to use tissue specimens. This work was authorized by the Research Ethics Committee of our hospital. All cases were treatment-naive prior to surgery, and all tissue specimens were immersed into liquid nitrogen promptly for RNA isolation.
Immunohistochemistry (IHC)
Immunostaining reagents for polyclonal anti-human PASD1 antibody were obtained from Abcam (ab 224362). Continuous sections of 4 μm thickness were prepared from formalin-fixed, paraffin embedded tissue. Subsequently, the sections were heated in citrate buffer (pH 6.0) for high-temperature antigen retrieval. After endogenous peroxidase was inactivated by 3% hydrogen peroxide, the sections were immunostained with anti-PASD1 polyclonal antibody (1: 200 dilution) or preimmune serum (negative control) overnight at 4°C. Then the treated sections were recovery at room temperature and incubated with biotinylated second antibodies (ZSGB-BIO, China). Lastly, immunoreactivity was visualized with 3, 3'-diaminobenzidine (DAB) (Maixin Biotechnology, China) followed by hematoxylin counterstain.
Cell lines and cell transfection
There were 4 glioma cell lines (U251, SHG-44, A172, and LN229), together with 1 human glial (HEB), cell line collected from the Type Culture Collection Cell Bank, of the Chinese Academy of Science Committee (Shanghai, China). Subsequently, cells were cultivated in DMEM (GIBCO-BRL, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, Gibco) in an incubator at 37°C and 5% CO 2 . For stabile knockdown of PASD1 in glioma cells, the shRNA sequence that specifically targeted PASD1 (sh-PASD1: 5'-CCAAGAAACAACAGAAACA-3') had been cloned into the lentiviral plasmid pLKO.1 puro (Addgene, Cambridge, MA, USA). Additionally, a scrambled shRNA sequence targeting none of the known gene (NC, 5'-CAUCGCAUCGUGUAATTTCTG-3') had also been processed in parallel as the negative control. Besides, pcDNA3.1 (control) and pcDNA3.1/PASD1 (specifically overexpress PASD1) was brought from Applied Biological Materials (ABM, Canada). Cells were transfected using the Lipofectamine 2000 kit (Thermo Fisher Scientific) in strict accordance with the manufacturer protocols.
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted from the collected tissues, which was then separated with the TRIzol reagent (Invitrogen, Grand Island, CA, USA). Subsequently, the isolated RNA would be reversely transcribed into cDNA using the PrimeScript RT reagent Kit (Takara, Japan) following manufacturer instructions. Afterwards, the SYBR Prime Script RT-PCR Kit (Takara, Japan) would be employed for qRT-PCR according to manufacturer instruction. All primers used in this study had been presented as follows: PASD1 primers, 5'-CTGTTAAGGTGGTGGCATTG-3' (forward), and 5'-GGAGGCTCATACTGGCTGAT-3' (reverse); GAPDH primers, 5'-CTCGCTTCGGCAGCACA-3' (forward), and 5'-AACGCTTCACGAATTTGCGT-3' (reverse). All experiments were carried out 3 times, and relative expression was calculated according to the 2 -DDCt method [6] and standardized based on GAPDH mRNA expression.
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Western blot analysis of the isolating proteins After being separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), cell protein lysates were first transferred onto polyvinylidene fluoride membranes (Roche), followed by incubation with specific rabbit anti-human antibodies (Abcam, Shanghai), including cyclin B1 (ab32053, 1: 3000 dilution), p-CDK1 (ab18, 1: 3000 dilution), cleaved caspase-3 (ab32042, 1: 5000 dilution), and cleaved caspase-9 (ab2324, 1: 5000 dilution). Subsequently, cells were stored at 4°C overnight, and incubated with the secondary anti-rabbit antibodies (A32732, 1: 1000 dilution, Thermo Fisher Scientific, American), where the ECL chromogenic substrate had been applied in quantification through densitometry (Quantity One software; Bio-Rad, Hercules, CA, USA).
Cell proliferation assay
Cell viability was assessed using the Cell Counting Kit 8 (CCK-8) kit (Dojindo Laboratories, Kumamoto, Japan). Afterwards, cells were seeded in a 96-well plate at a density of 1×10 4 cells/well. After 24 hours of culture, the corresponding sh-PASD1 and NC were transfected and cultivated in the normal mediums. Later, the CCK-8 solution was added at 0, 24, 48 and 72 hours, and relative cell number was evaluated at the wavelength of 450 nm. All assays were performed 3 times.
Colony forming assay
After trypsin digestion, an appropriate number of transfected cells were seeded into the culture dish and cultivated in DMED supplemented with 10% FBS for 2 weeks. Afterwards, cells were fixed with paraformaldehyde and stained with crystal violet (Beyotime, Haimen, China). Subsequently, cells were air-dried, and photos were used to count the visible colonies. 
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Results
PASD1 was elevated in glioma
To explore the role of PASD1 in glioma, PASD1 expression in glioma as well as normal adjacent tissue specimens was detected among the 155 glioma samples through immunohistochemical (IHC) staining, along with PASD1 specific antibody testing. As was seen in our results, positive staining was mainly observed in cytoplasm as well as nucleus ( Figure 1A-1C ) with pre-immune serum as negative control ( Figure 1D) . Moreover, the intensity of staining indicated that high and low PASD1 protein expression levels were 67.10% (104 out of 155) and 32.90% (51 out of 155), respectively (Table 1) . At the same time, 5 normal cerebral tissues were detected, which suggested that PASD1 was rarely detected in normal cerebral specimens ( Figure 1C ). In addition, relative PASD1 levels in glioma specimens were detected through western blot and qRT-PCR, and were shown to be markedly upregulated relative to that in normal cerebral specimens (P<0.001) ( Figure 1E, 1F ). Furthermore, PASD1 was also over-expressed in glioma cell lines compared with that in human glial (HEB) cell line (P<0.05) whether in protein level or mRNA level (Figure 2A, 2B) . Therefore, the LN229 cell line with the highest PASD1 expression was selected to downregulate PASD1 through infection with the PASD1-specific sh-PASD1 (sh-NC was used as the control) ( Figure 2C, 2D) . 
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Higher PASD1 expression was related to the poorer prognosis among glioma patients PASD1 was over-expressed in glioma; therefore, it was proposed that PASD1 expression might be associated with the pathogenesis of glioma. As shown in Table 1 , PASD1 expression was detected to be markedly correlated with gender (P=0.004), WHO grade (P=0.02) as well as p53% (P=0.000), but not with age of patient (P=0.141), tumor size (P=0.21), Ki-67 (P=0.106) or KPS score (P=0.430). Moreover, high PASD1 expression could be used as an independent factor to predict the prognosis of glioma patients ( Table 2 , P=0.000). Likewise, Figure 1G showed that high PASD1 expression was associated with the dismal prognosis for glioma patients (P<0.05). Taken together, these findings indicated the potential of PASD1 as a detrimental prognosis factor in glioma.
PASD1 promoted cell proliferation through inhibiting apoptosis in vitro
Results of the CCK-8 assay revealed that transfection with sh-PASD1 could remarkably reduce the proliferation rate of LN229 compared with that in cells transfected with sh-RNA (P<0.01, Figure 2E ). Similarly, results of colony forming assay indicated that PASD1 downregulation could lead to decreased proliferation relative to that in the control group (P<0.05; Figure 2F ).
Disturbance of the cell cycle could result in persistent cell proliferation [7] ; as a result, flow cytometry could be utilized to detect whether PASD1 could impair the cell cycle. Our results showed that, PASD1 knockdown could dramatically reduce the number of cells at S phase, along with increased number of cells at G2/M phase relative to those in the control group (P<0.05, Figure 3A ). Moreover, cell counts at G0/G1 phase displayed a statistically significant difference. Meanwhile, western blot assay was performed to further verify the influence of PASD1 on the proliferation of glioma. As shown in Figure 3B , cyclin B1 expression was evidently upregulated in sh-PASD1 transfected cells (P<0.05). Meanwhile, cyclin-dependent kinase 1 (CDK1) expression was markedly downregulated compared with that in the control group (P<0.05). Moreover, flow cytometry was performed to further verify whether PASD1 could regulate cell proliferation through interfering cell apoptosis. As presented in Figure 4A , downregulating PASD1 in the LN229 cell lines accelerated cell apoptosis (P<0.01; Figure 3C ). Therefore, the protein expression levels of cleaved caspase-3 as well as cleaved caspase-9 were evaluated; in the meantime, the levels of apoptosis markers belonging to the caspase family, together with p53, a well-known pro-apoptotic protein, were also detected. As presented in Figure 3D , compared with the control group, downregulating PASD1 could upregulate the levels of cleaved caspase-3, cleaved caspase-9, and p53 (P<0.01; Figure 3D ). Therefore, PASD1 downregulation in glioma cells would inhibit Table 2 . Cox proportional Hazards model was used to analyze the effect of PASD1 expression on the survival of glioma patients.
Univariate analysis was performed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model. HR -Hazard ratio; 95%CI -95 percent confidence interval for relative risk. * Statistically significant (P<0.05); ** statistically significant (P<0.01); *** statistically significant (P<0.00). 
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the proliferation ability of cells and result in cell arrest at G2/M phase by accelerating apoptosis. Then, rescue assays were applied to further illuminate that the function of PASD1 in glioma. Satisfactory transfection efficiency of PASD1-overexpression was detected in the A172 cell line (P<0.05; Figure 4A ). After cotransfected with sh-PASD1 and pcDNA3.1/PASD1 in the LN229 cell line ( Figure 4B ), CCK8 assays and colony formation assays were performed. As revealed in Figure 4C and 4D, the reducing of proliferation induced by downregulation of PASD1 was restored by co-transfecting pcDNA3.1/PASD1 in the LN229 cell line. Additionally, as shown in Figure 4E , co-transfection with pcDNA3.1/PASD1 recovered the enhancing of apoptosis induced by PASD1 upregulation. Similarly, up-expression of cleaved caspase-3, cleaved caspase-9, and p53 were reduced by co-transfection with pcDNA3.1/PASD1 (P <0.05; Figure 4F ). These data indicated that PASD1 promoted cell proliferation through inhibiting apoptosis in vitro.
Discussion
Nowadays, an increasing number of studies have revealed the relationship between cancer-associated cancer-testis antigen (CTAs) and the tumorigenesis of various cancers. Moreover, many CTAs have been identified to play a vital role in glioma. Li et al. revealed that high OY-TES-1 expression could be detected in glioma tissues; besides, the anti-OY-TES-1 antibodies existed in the serum of 5 out of 36 glioma patients (14%), which could not be detected in the serum samples from 107 healthy donors [6] . Saito et al. demonstrated that KIF20A was a tumor-associated antigen, which was involved in the growth and survival of glioma cells, suggesting that KIF20A was an onco-antigen as well as a candidate novel immunotherapeutic target for glioma [7] . On the other hand, Deng et al. declared that multiple CTAs, such as ADAMTS1, ADAM23, SPANXA1, SPANXB1/2, IL13RA2, VCY, and VCX3A, had been upregulated in pediatric glioma, which was correlated with pediatric gliomagenesis [8] . Therefore, CTAs can potentially serve as prognostic factors and diagnostic biomarkers for glioma. However, the molecular mechanism by which PASD1 affects glioma cells remains largely unknown.
PASD1 was originally identified as a CTA in diffuse large B cell lymphoma [8] , and was discovered to be expressed in many other human cancers, including various hematological malignancies such as acute myeloid leukemia [9] , Burkitt's lymphoma [9] , Hodgkin's lymphoma [10] , and multiple myeloma [10] , as well as solid tumors like melanoma [11] , lung cancer [12] , head and neck cancer [11] , cervical cancer [13] , and colorectal carcinoma [14] . PASD1 has become a promising immunotherapeutic target for many cancers, which can be ascribed to its restricted expression and good immunogenicity [14] .
Recently, PASD1 was reported to positively regulate IL-6-STAT3 signaling, which facilitates tumor growth [14] . In our experiment, high PASD1 expression was also be detected in glioma tissues compared with that in adjacent tissues. Additionally,
